Premium
Human mesenchymal stem cells: From immunophenotyping by flow cytometry to clinical applications
Author(s) -
Nery Arthur A.,
Nascimento Isis C.,
Glaser Talita,
Bassaneze Vinicius,
Krieger José E.,
Ulrich Henning
Publication year - 2013
Publication title -
cytometry part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.316
H-Index - 90
eISSN - 1552-4930
pISSN - 1552-4922
DOI - 10.1002/cyto.a.22205
Subject(s) - mesenchymal stem cell , immunophenotyping , cd90 , stem cell , cd34 , regenerative medicine , medicine , cell therapy , pathology , flow cytometry , cluster of differentiation , bone marrow , clinical uses of mesenchymal stem cells , transplantation , immunology , biology , cancer research , cellular differentiation , adult stem cell , microbiology and biotechnology , cell , genetics , biochemistry , gene
Modern medicine will unequivocally include regenerative medicine as a major breakthrough in the re‐establishment of damaged or lost tissues due to degenerative diseases or injury. In this scenario, millions of patients worldwide can have their quality of life improved by stem cell implantation coupled with endogenous secretion or administration of survival and differentiation promoting factors. Large efforts, relying mostly on flow cytometry and imaging techniques, have been put into cell isolation, immunophenotyping, and studies of differentiation properties of stem cells of diverse origins. Mesenchymal stem cells (MSCs) are particularly relevant for therapy due to their simplicity of isolation. A minimal phenotypic pattern for the identification of MSCs cells requires them to be immunopositive for CD73, CD90, and CD105 expression, while being negative for CD34, CD45, and HLA‐DR and other surface markers. MSCs identified by their cell surface marker expression pattern can be readily purified from patient's bone marrow and adipose tissues. Following expansion and/or predifferentiation into a desired tissue type, stem cells can be reimplanted for tissue repair in the same patient, virtually eliminating rejection problems. Transplantation of MSCs is subject of almost 200 clinical trials to cure and treat a very broad range of conditions, including bone, heart, and neurodegenerative diseases. Immediate or medium term improvements of clinical symptoms have been reported as results of many clinical studies. © 2012 International Society for Advancement of Cytometry